Emergent BioSolutions | EBS - Cash And Equivalent


Emergent BioSolutions reported $111.7M in Cash and Equivalent for its fiscal quarter ending in December of 2023.





Cash And Equivalent Change Date
Acadia Pharmaceuticals USD 976.45M 19.97M Sep/2026
Akebia Therapeutics USD 159.25M 3.71M Sep/2026
ALKERMES USD 631.31M 119.78M Sep/2026
Alnylam Pharmaceuticals USD 1.75B 46.02M Sep/2026
Amarin USD 156.51M 12.95M Sep/2026
ANI Pharmaceuticals USD 420.76M 60.55M Sep/2026
BioMarin Pharmaceutical USD 736.01M 138M Sep/2026
Coherus Biosciences USD 82.92M 32.32M Jun/2026
Emergent BioSolutions USD 111.7M 23.9M Dec/2023
Exelixis USD 304.77M 23.33M Sep/2026
Glaxosmithkline GBP 2.93B 508M Sep/2026
Heron Therapeutics USD 20.72M 5.4M Jun/2026
Ionis Pharmaceuticals USD 350.06M 1.57B Jun/2026
Ironwood Pharmaceuticals USD 86.38M 7.25M Sep/2026
Lexicon Pharmaceuticals USD 38.09M 3.76M Mar/2026
Lonza CHF 719M 188M Dec/2025
Merck USD 9.55B 2.7B Sep/2026
Moderna USD 1.2B 528M Sep/2026
Myriad Genetics USD 115.2M 9.2M Jun/2026
Nektar Therapeutics USD 149.58M 134.46M Mar/2026
Neurocrine Biosciences USD 641.5M 309.1M Sep/2026
Pacira USD 1.79B 1.58B Sep/2026
Pfizer USD 1.82B 848M Sep/2026
PTC Therapeutics USD 508.89M 540.99M Sep/2026
Sanofi EUR 6.35B 806M Jun/2026
Sarepta Therapeutics USD 472.76M 98.39M Sep/2026
United Therapeutics USD 1.19B 614.3M Sep/2026
Vanda Pharmaceuticals USD 84.85M 14.83M Dec/2025